<DOC>
	<DOCNO>NCT01087151</DOCNO>
	<brief_summary>This Phase II , randomize , open-label , international , multicenter trial design evaluate safety efficacy rituximab monotherapy give accord dose intense regimen assess safety , efficacy , pharmacokinetics ABT-263 combine dose-intense rituximab previously untreated patient B-cell CLL .</brief_summary>
	<brief_title>A Study ABT-263 Combination With Dose-Intensive Rituximab , Dose-Intensive Rituximab Alone , Previously Untreated Patients With B-Cell , Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Previously untreated , CD20positive Bcell CLL ECOG performance status 0 1 Life expectancy &gt; 6 month Willingness capability accessible followup study termination death For patient reproductive potential ( male female ) , use reliable mean contraception Prolymphocytic leukemia Richter 's transformation aggressive Bcell malignancy ( e.g. , DLBCL ) Prior radiotherapy lesion ( ) use assess response unless lesion ( ) show clear evidence progression baseline Patients history malignancy within 2 year prior study entry except adequately treat carcinoma situ cervix , basal squamous cell skin carcinoma , lowgrade , localized prostate cancer treat surgically curative intent one carry good prognosis , situ ductal carcinoma breast treat lumpectomy alone curative intent Prior treatment rituximab , ABT263 proapoptotic agent Current recent ( within 28 day prior initiation study treatment ) participation another experimental drug study Major surgical procedure ( exclude lymph node biopsy ) significant traumatic injury within 28 day prior treatment onset anticipation need major surgery course study Active infection require parenteral antibiotic antiviral antifungal agent onset study treatment Receipt primary booster vaccination livevirus vaccine 6 month prior initiation study treatment Patients receive therapeutic anticoagulation heparin warfarin patient receive drug herbal supplement know inhibit platelet function ( include lowdose aspirin ) within 7 day first dose ABT263 . Note : Patients receive lowdose anticoagulation purpose maintain central venous catheter patency eligible . Patients inherit acquired bleeding diathesis , include ( limited ) hemophilia immune thrombotic thrombocytopenic purpura , underlie condition predisposes abnormal bleeding ( e.g. , peptic ulcer disease ) within 1 year prior first dose ABT263 Patients history refractoriness platelet transfusion Clinically significant cardiovascular disease Known human immunodeficiency virus ( HIV ) infection , seropositivity hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) antibody RNA Pregnancy breastfeed Concurrent ( within 7 day prior first dose study treatment ) systemic corticosteroid therapy except lowdose corticosteroid therapy History disease , metabolic dysfunction , physical laboratory finding ( ) give reasonable suspicion disease condition contraindicate use investigational drug , might affect interpretation result study render patient high risk treatment complication History anaphylaxis , allergic reaction , hypersensitivity sulfites ( sodium metabisulphite include study drug formulation ) Any contraindication alcohol ingestion ( study drug formulation include approximately 15 % ethanol )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rituxan</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>BCl-2</keyword>
</DOC>